Ultradeformable liposomal delivery of vismodegib modulates its biological activity in melanoma cells
Maria Natalia Calienni, Cristian Sandoval-Acuña, Petra Potomová, David Emanuel Ybarra, Jaroslav Truksa, Jorge Montanari · 2026
Read Ultradeformable liposomal delivery of vismodegib modulates its biological activity in melanoma cells by Maria Natalia Calienni, Cristian Sandoval-Acuña, Petra Potomová, David Emanuel Ybarra, Jaroslav Truksa, Jorge Montanari (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13295005.txt.
Description
Maria Natalia Calienni and colleagues wrap a skin cancer drug in squishy carriers to change how it behaves, in a 2026 study. Vismodegib blocks the Hedgehog signaling pathway and is approved for basal cell carcinoma, but swallowing it brings real side effects and getting it into skin tumors is hard. The team first screened the free drug on four mouse tumor cell lines, then loaded it into ultradeformable liposomes, flexible fat bubbles designed for topical use, and tested them on melanoma cells.
Melanoma cells answered the free drug most strongly among the lines screened. Once wrapped, the drug killed more melanoma cells and slowed their expansion more than the free form at matched doses, beyond what pathway blocking alone explains. A tree-like dendrimer carrier, tried for comparison, showed no detectable effect at safe levels. The authors back skin-applied nanocarriers as a repurposing route for early melanoma.
Catalog record
| CREATOR | Maria Natalia Calienni, Cristian Sandoval-Acuña, Petra Potomová, David Emanuel Ybarra, Jaroslav Truksa, Jorge Montanari |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |